Skip to main content
VTYX
NASDAQ Life Sciences

Ventyx Biosciences to be Acquired by Eli Lilly in Transformational Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
10
Price
$13.74
Mkt Cap
$979.754M
52W Low
$0.783
52W High
$25
52W Position info
1655% above low
Off High info
45% below high
Rel. Volume info
5.8× avg
Market data snapshot near publication time

VTYX has more than doubled off its 52-week low of $0.783 on elevated volume (5.8× avg).

Summary

Ventyx Biosciences announced it has agreed to be acquired by Eli Lilly, a move expected to accelerate its pipeline development and patient reach.


Key Events · M&A and Partnerships · VTYX

  • Acquisition Agreement

    Ventyx Biosciences has entered into a definitive agreement to be acquired by Eli Lilly and Company.

  • Strategic Rationale

    The acquisition is expected to accelerate Ventyx's ability to treat more patients by leveraging Lilly's infrastructure, resources, and expertise, particularly for its pipeline in autoimmune, inflammatory, and neurodegenerative diseases.

  • Expected Closing

    The transaction is anticipated to be completed in the first half of 2026, subject to customary closing conditions, including regulatory approvals and Ventyx stockholder approval.

  • Operational Continuity

    Until the transaction closes, Ventyx Biosciences will continue to operate as an independent company, with business as usual.


Analysis · VTYX · Life Sciences

Ventyx Biosciences has announced a definitive agreement to be acquired by Eli Lilly, a major pharmaceutical company. This acquisition represents a fundamental change for Ventyx, transitioning it from an independent entity to a part of a larger, well-resourced organization. The deal is expected to significantly accelerate the development and market reach of Ventyx's pipeline, particularly in autoimmune, inflammatory, and neurodegenerative diseases, by leveraging Lilly's extensive infrastructure and expertise. Investors should monitor the progress towards closing, including regulatory approvals and stockholder vote, as the transaction is anticipated to complete in the first half of 2026.

At the time of this filing, VTYX was trading at $13.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $979.8M. The 52-week trading range was $0.78 to $25.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTYX - Latest Insights

VTYX
Mar 05, 2026, 9:00 AM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.99 info
Change: $0 (0%) info
Market Cap: $1.005B info
VTYX
Mar 04, 2026, 9:22 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $13.99
Real-time Price: $13.99 info
Change: $0 (0%) info
Market Cap: $1.005B info
VTYX
Mar 03, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.99
Real-time Price: $13.99 info
Change: $0 (0%) info
Market Cap: $1.005B info
VTYX
Feb 23, 2026, 4:29 PM EST
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $13.96
Real-time Price: $13.99 info
Change: +$0.030 (+0.21%) info
Market Cap: $1.005B info
VTYX
Feb 23, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $13.99 info
Change: +$0.030 (+0.21%) info
Market Cap: $1.005B info